All Stories

  1. Platelets derived citrullinated proteins and microparticles are potential autoantibodies ACPA targets in RA patients
  2. Vaccines and Vaccine Adjuvants for Infectious Diseases and Autoimmune Diseases
  3. Comparative studies on mannan and imiquimod induced experimental plaque psoriasis inflammation in inbred mice
  4. Kaempferol modulates IFN-γ induced JAK-STAT signaling pathway and ameliorates imiquimod-induced psoriasis-like skin lesions
  5. Editorial: Systemic lupus erythematosus - predisposition factors, pathogenesis, diagnosis, treatment and disease models
  6. Small molecule SMU-CX24 targeting toll-like receptor 3 counteracts inflammation: A novel approach to atherosclerosis therapy
  7. HAPLN1 Affects Cell Viability and Promotes the Pro-Inflammatory Phenotype of Fibroblast-Like Synoviocytes
  8. Estrogen Acts Through Estrogen Receptor-β to Promote Mannan-Induced Psoriasis-Like Skin Inflammation
  9. Characterization of chronic relapsing antibody mediated arthritis in mice with a mutation in Ncf1 causing reduced oxidative burst
  10. Proteus mirabilis Vesicles Induce Mitochondrial Apoptosis by Regulating miR96-5p/Abca1 to Inhibit Osteoclastogenesis and Bone Loss
  11. A Perspective on the Roles of Adjuvants in Developing Highly Potent COVID-19 Vaccines
  12. Gancao Nurish-Yin Decoction medicated serum inhibits growth and migration of ovarian cancer cells: network pharmacology-based analysis and biological validation
  13. Targeting microRNA for improved skin health
  14. Albumin/Globulin Ratio as Yin–Yang in Rheumatoid Arthritis and Its Correlation to Inflamm-Aging Cytokines
  15. Polymorphic estrogen receptor binding site causes Cd2-dependent sex bias in the susceptibility to autoimmune diseases
  16. Current Progress in the Development of Zika Virus Vaccines
  17. Optimization of CAR-T Cell-Based Therapies Using Small-Molecule-Based Safety Switches
  18. Imidazole Scaffold based Compounds in the Development of Therapeutic Drugs
  19. Design, Synthesis, and Structure–Activity Relationship of N-Aryl-N′-(thiophen-2-yl)thiourea Derivatives as Novel and Specific Human TLR1/2 Agonists for Potential Cancer Immunotherapy
  20. Comparative Analysis on Abnormal Methylome of Differentially Expressed Genes and Disease Pathways in the Immune Cells of RA and SLE
  21. Polymorphic estrogen receptor binding site causes CD2-dependent sex bias in the susceptibility to autoimmune diseases
  22. ‘SMASH’ recommendations for standardised microscopic arthritis scoring of histological sections from inflammatory arthritis animal models
  23. Targeted inhibition of ATP5B gene prevents bone erosion in collagen-induced arthritis by inhibiting osteoclastogenesis
  24. Emerging and state of the art hemagglutinin-targeted influenza virus inhibitors
  25. Structural Insights into the Atomistic Mechanisms of Uric Acid Recognition and Translocation of Human Urate Anion Transporter 1
  26. Design and pharmaceutical applications of proteolysis-targeting chimeric molecules
  27. Gancao Nurish-Yin Decoction Ameliorates Imiquimod-Induced Psoriasis-Like Skin Lesions and Inflammation in Mice
  28. Genetic dissection of a major haplotype associated with arthritis reveal FcγR2b and FcγR3 to act additively
  29. Collagen-induced inflammations
  30. Potential treatment methods targeting 2019-nCoV infection
  31. Vitamin D3 receptor polymorphisms regulate T cells and T cell-dependent inflammatory diseases
  32. Recent Research on Flavonoids and their Biomedical applications
  33. Phytoestrogens protect joints in collagen induced arthritis by increasing IgG glycosylation and reducing osteoclast activation
  34. Cartilage-binding antibodies initiate joint inflammation and promote chronic erosive arthritis
  35. Metformin, AMPK activator inhibits activation of fibroblast-like synoviocytes but promotes hyaluronan and proteoglycan link protein 1 secretion
  36. SNX10 deficiency restricts foam cell formation and protects against atherosclerosis by suppressing CD36-Lyn axis
  37. Molecular and Cellular Pathways Contributing to Joint Damage in Rheumatoid Arthritis
  38. Adenosine monophosphate-activated protein kinase activator inhibits activation of fibroblast-like synoviocytes but promotes hyaluronan and proteoglycan link protein 1 secretion
  39. [1,2,4]Triazolo[1,5-a]pyrimidine derivative (Mol-5) is a new NS5-RdRp inhibitor of DENV2 proliferation and DENV2-induced inflammation
  40. Autoantibodies as Diagnostic Markers and Mediator of Joint Inflammation in Arthritis
  41. GLP-1 Receptor Activation Abrogates β-Cell Dysfunction by PKA Cα-Mediated Degradation of Thioredoxin Interacting Protein
  42. Asperosaponin VI protects against bone destructions in collagen induced arthritis by inhibiting osteoclastogenesis
  43. Immunotherapy for treating methamphetamine, heroin and cocaine use disorders
  44. SNX10 (sorting nexin 10) inhibits colorectal cancer initiation and progression by controlling autophagic degradation of SRC
  45. Cartilage-binding antibodies induce pain through immune complex–mediated activation of neurons
  46. Protective effects of Wang-Bi tablet on bone destruction in collagen-induced arthritis by regulating osteoclast-osteoblast functions
  47. Autophagy induced by STING, an unnoticed and primordial function of cGAS
  48. Regulatory role of Golgi brefeldin A resistance factor‐1 in amyloid precursor protein trafficking, cleavage and Aβ formation
  49. Therapeutic effects of artesunate on lupus-prone MRL/lpr mice are dependent on T follicular helper cell differentiation and activation of JAK2-STAT3 Signaling Pathway
  50. Analysis of data from breast diseases treated with 5-alpha reductase inhibitors for benign prostatic hyperplasia
  51. TLR1/2 Specific Small‐Molecule Agonist Suppresses Leukemia Cancer Cell Growth by Stimulating Cytotoxic T Lymphocytes
  52. The autoantibody response to cyclic citrullinated collagen type II peptides in rheumatoid arthritis
  53. Nanobiocatalysts for Industrial Applications
  54. Large expert-curated database for benchmarking document
  55. Streptococcal Endo-β-N-Acetylglucosaminidase Suppresses Antibody-Mediated Inflammation In Vivo
  56. Antigen-Specific Tolerization and Targeted Delivery as Therapeutic Strategies for Autoimmune Diseases
  57. Chronic Active Arthritis Driven by Macrophages Without Involvement of T Cells
  58. Q63, a novel DENV2 RdRp non-nucleoside inhibitor, inhibited DENV2 replication and infection
  59. Recent advances in the development of vaccines for chronic inflammatory autoimmune diseases
  60. A Shared Epitope of Collagen Type XI and Type II Is Recognized by Pathogenic Antibodies in Mice and Humans with Arthritis
  61. Increased salt exposure affects both lymphoid and myeloid effector functions, influencing innate-associated disease but not T-cell-associated autoimmunity
  62. A Restricted Role for FcγR in the Regulation of Adaptive Immunity
  63. Tatanan A from the Acorus calamus L . root inhibited dengue virus proliferation and infections
  64. Targeting IgG in Arthritis: Disease Pathways and Therapeutic Avenues
  65. An update on smart biocatalysts for industrial and biomedical applications
  66. Inhibition of dengue viral infection by diasarone-I is associated with 2'O methyltransferase of NS5
  67. Germinal Center B Cells Are Essential for Collagen-Induced Arthritis
  68. Targeting pattern-recognition receptors to discover new small molecule immune modulators
  69. Biomaterials for Induction and Treatment of Autoimmunity
  70. Regulation of autoantibody activity by the IL-23–TH17 axis determines the onset of autoimmune disease
  71. Animal Models of Rheumatoid Arthritis (I): Pristane-Induced Arthritis in the Rat
  72. Autoantibodies to citrullinated proteins induce joint pain independent of inflammation via a chemokine-dependent mechanism
  73. Macrophage-derived reactive oxygen species protects against autoimmune priming with a defined polymeric adjuvant
  74. System A amino acid transporters regulate glutamine uptake and attenuate antibody-mediated arthritis
  75. B-cell epitope spreading and inflammation in a mouse model of arthritis is associated with a deficiency in reactive oxygen species production
  76. Reactive Oxygen Species in Psoriasis and Psoriasis Arthritis: Relevance to Human Disease
  77. Nerve Conduction Velocity Is Regulated by the Inositol Polyphosphate-4-Phosphatase II Gene
  78. Mannan induces ROS-regulated, IL-17A–dependent psoriasis arthritis-like disease in mice
  79. Synthetic Polymer as an Adjuvant in Collagen‐Induced Arthritis
  80. A Single Functional Group Substitution in C5a Breaks B Cell and T Cell Tolerance and Protects Against Experimental Arthritis
  81. Epitope-specific antibody response is controlled by immunoglobulin VHpolymorphisms
  82. Chemical cross-linking abrogates adjuvant potential of natural polymers
  83. Affinity purified anti-citrullinated protein/peptide antibodies target antigens expressed in the rheumatoid joint
  84. Type II collagen antibody response is enriched in the synovial fluid of rheumatoid joints and directed to the same major epitopes as in collagen induced arthritis in primates and mice
  85. Polymeric cryogels are biocompatible, and their biodegradation is independent of oxidative radicals
  86. Stimuli‐Responsive Polymers as Adjuvants and Carriers for Antigen Delivery
  87. Incomplete B Cell Tolerance to Cartilage Oligomeric Matrix Protein in Mice
  88. Characterization of chemically defined poly-N-isopropylacrylamide based copolymeric adjuvants
  89. Dominant suppression of inflammation by glycan-hydrolyzed IgG
  90. Type II collagen–specific antibodies induce cartilage damage in mice independent of inflammation
  91. Collagen antibody–induced arthritis evokes persistent pain with spinal glial involvement and transient prostaglandin dependency
  92. Applications of polymeric adjuvants in studying autoimmune responses and vaccination against infectious diseases
  93. Genetic control of antibody production during collagen‐induced arthritis development in heterogeneous stock mice
  94. C57BL/6 mice need MHC class II Aq to develop collagen-induced arthritis dependent on autoreactive T cells
  95. Correction: Pathogenic Autoreactive B Cells Are Not Negatively Selected toward Matrix Protein Collagen II
  96. Keratinocyte growth factor (KGF) delays the onset of collagen-induced arthritis
  97. Enhancement of Antibody-Induced Arthritis via Toll-Like Receptor 2 Stimulation Is Regulated by Granulocyte Reactive Oxygen Species
  98. Antibody‐Mediated Arthritis and New Therapeutic Avenues
  99. Genetic control of antibody production during collagen induced arthritis development in heterogeneous stock mice
  100. Identification of arthritis promoting non-obese diabetic genes in theCia9locus using different genetic strategies
  101. Collagen Antibody-Induced Arthritis: A Disease-Relevant Model for Studies of Persistent Joint Pain
  102. Cartilage oligomeric matrix protein specific antibodies are pathogenic
  103. Crystal structure of an arthritogenic anticollagen immune complex
  104. Collagen Type II and a Thermo-Responsive Polymer of N-Isopropylacrylamide Induce Arthritis Independent of Toll-Like Receptors
  105. Pathogenic Autoreactive B Cells Are Not Negatively Selected toward Matrix Protein Collagen II
  106. Inhibiting the C5–C5a receptor axis
  107. An encephalomyelitis-specific locus on chromosome 16 in mouse controls disease development and expression of immune-regulatory genes
  108. A dominant suppressive MHC class II haplotype interacting with autosomal genes controls autoantibody production and chronicity of arthritis
  109. High-resolution mapping of a complex disease, a model for rheumatoid arthritis, using heterogeneous stock mice
  110. Adjuvant properties of a biocompatible thermo-responsive polymer of N-isopropylacrylamide in autoimmunity and arthritis
  111. Effects of oestradiol and raloxifene on the induction and effector phases of experimental postmenopausal arthritis and secondary osteoporosis
  112. Cystatin C influences the autoimmune but not inflammatory response to cartilage type II collagen leading to chronic arthritis development
  113. Collagen antibody-induced arthritis (CAIA) evokes transient inflammation but persistent allodynia
  114. Correction: A Recombinant Vaccine Effectively Induces C5a-Specific Neutralizing Antibodies and Prevents Arthritis
  115. Chemical changes demonstrated in cartilage by synchrotron infrared microspectroscopy in an antibody-induced murine model of rheumatoid arthritis
  116. Heterogeneous Stock Mice are Susceptible to Encephalomyelitis and Antibody-initiated Arthritis but not to Collagen- and G6PI-induced Arthritis
  117. Specific antibody protection of the extracellular cartilage matrix against collagen antibody–induced damage
  118. A Recombinant Vaccine Effectively Induces C5a-Specific Neutralizing Antibodies and Prevents Arthritis
  119. Pain mechanisms in animal models of rheumatoid arthritis
  120. Rabeximod reduces arthritis severity in mice by decreasing activation of inflammatory cells
  121. Antibodies to citrullinated proteins: molecular interactions and arthritogenicity
  122. In vivo imaging of reactive oxygen and nitrogen species in inflammation using the luminescent probe L-012
  123. Secretory lysosome targeting and induced secretion of human soluble TNF-α receptor in murine hematopoietic cells in vivo as a principle for immunoregulation in inflammation and malignancy
  124. Pathogenic antibody recognition of cartilage
  125. Structure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritis
  126. The role of collagen antibodies in mediating arthritis
  127. Three‐dimensional culture for monoclonal antibody production by hybridoma cells immobilized in macroporous gel particles
  128. Role of anti-hinge antibodies in therapeutic cleavage of IgG: response to Drs. Lutz and Fumia
  129. C4b-binding protein (C4BP) inhibits development of experimental arthritis in mice
  130. The novel small molecule drug Rabeximod is effective in reducing disease severity of mouse models of autoimmune disorders
  131. Diagnosis of typhoid fever: detection of Salmonella typhi porins-specific antibodies by inhibition ELISA
  132. Cartilage oligomeric matrix protein induction of chronic arthritis in mice
  133. The role of collagen antibodies in mediating arthritis
  134. Therapeutic cleavage of IgG: new avenues for treating inflammation
  135. The crystal structure of the pathogenic collagen type II-specific mouse monoclonal antibody CIIC1 Fab: Structure to function analysis
  136. Cartilage oligomeric matrix protein deficiency promotes early onset and the chronic development of collagen-induced arthritis
  137. Arthritogenic antibodies specific for a major type II collagen triple‐helical epitope bind and destabilize cartilage independent of inflammation
  138. Macrophages suppress T cell responses and arthritis development in mice by producing reactive oxygen species
  139. Blocking of experimental arthritis by cleavage of IgG antibodies in vivo
  140. Endoglycosidase treatment abrogates IgG arthritogenicity: Importance of IgG glycosylation in arthritis
  141. Monoclonal Antibody Production Using a New Supermacroporous Cryogel Bioreactor
  142. Ethanol prevents development of destructive arthritis
  143. Collagen Antibody Induced Arthritis
  144. Monoclonal Antibody Production Using a New Supermacroporous Cryogel Bioreactor
  145. Backcross and Partial Advanced Intercross Analysis of Nonobese Diabetic Gene-Mediated Effects on Collagen-Induced Arthritis Reveals an Interactive Effect by Two Major Loci
  146. Do “infectious” prey select for high levels of natural antibodies in tropical pythons?
  147. Arthritis induced with cartilage‐specific antibodiesis IL‐4‐dependent
  148. Therapeutic Vaccination of Active Arthritis with a Glycosylated Collagen Type II Peptide in Complex with MHC Class II Molecules
  149. Integrated bioprocess for the production and isolation of urokinase from animal cell culture using supermacroporous cryogel matrices
  150. Type IX collagen deficiency enhances the binding of cartilage-specific antibodies and arthritis severity
  151. Stromal cells and osteoclasts are responsible for exacerbated collagen‐induced arthritis in interferon‐β–deficient mice
  152. Efficient promotion of collagen antibody induced arthritis (CAIA) using four monoclonal antibodies specific for the major epitopes recognized in both collagen induced arthritis and rheumatoid arthritis
  153. Arthritogenic anti–type II collagen antibodies are pathogenic for cartilage‐derived chondrocytes independent of inflammatory cells
  154. Methotrexate ameliorates T cell dependent autoimmune arthritis and encephalomyelitis but not antibody induced or fibroblast induced arthritis
  155. A genetic contamination in MHC‐congenic mouse strains reveals a locus on chromosome 10 that determines autoimmunity and arthritis susceptibility
  156. The Plasminogen Activator/Plasmin System Is Essential for Development of the Joint Inflammatory Phase of Collagen Type II-Induced Arthritis
  157. Identification of epistasis through a partial advanced intercross reveals three arthritis loci within the Cia5 QTL in mice
  158. Affinity binding of cells to cryogel adsorbents with immobilized specific ligands: effect of ligand coupling and matrix architecture
  159. Antileukoproteinase: Modulation of neutrophil function and therapeutic effects on anti–type II collagen antibody–induced arthritis
  160. Two monoclonal antibodies to precisely the same epitope of type II collagen select non-crossreactive phage clones by phage display: implications for autoimmunity and molecular mimicry
  161. Complement activation by both classical and alternative pathways is critical for the effector phase of arthritis
  162. Relapsing Polychondritis, Induced in Mice with Matrilin 1, Is an Antibody- and Complement-Dependent Disease
  163. Collagen Type II-Specific Monoclonal Antibody-Induced Arthritis in Mice
  164. Genetic Control of Tolerance to Type II Collagen and Development of Arthritis in an Autologous Collagen-Induced Arthritis Model
  165. Induction of arthritis by single monoclonal IgG anti‐collagen type II antibodies and enhancement of arthritis in mice lacking inhibitory FcγRIIB
  166. IL-4-deficient mice develop less acute but more chronic relapsing collagen-induced arthritis
  167. Epitope‐specific recognition of type II collagen by rheumatoid arthritis antibodies is shared with recognition by antibodies that are arthritogenic in collagen‐induced arthritis in the mouse
  168. Mouse models for rheumatoid arthritis
  169. IL-10-Deficient B10.Q Mice Develop More Severe Collagen-Induced Arthritis, but Are Protected from Arthritis Induced with Anti-Type II Collagen Antibodies
  170. Evaluation of the Percentage of Peripheral T Cells with Two Different T Cell Receptor α-Chains and of their Potential Role in Autoimmunity
  171. Influence of Immunopotentiators on the Antiporin Immunoglobulin G Subclass: Distribution and Protective Immunity Against Murine Salmonellosis
  172. Monoclonal antibodies against Salmonella porins: Generation and characterization
  173. Applications of Nanomaterials for Activation and Suppression of Immune Responses
  174. Applications of Nanomaterials for Activation and Suppression of Immune Responses